{
  "QNTM": [],
  "LTRY": [],
  "LIPO": [
    {
      "author": "Benzinga Newsdesk",
      "content": "",
      "created_at": "2025-02-06T11:02:46Z",
      "headline": "Lipella Pharmaceuticals Receives FDA Approval For Expanded Access Program For LP-310 In Oral Lichen Planus",
      "id": 43522325,
      "images": [],
      "source": "benzinga",
      "summary": "",
      "symbols": [
        "LIPO"
      ],
      "updated_at": "2025-02-06T11:02:46Z",
      "url": "https://www.benzinga.com/news/25/02/43522325/lipella-pharmaceuticals-receives-fda-approval-for-expanded-access-program-for-lp-310-in-oral-lichen",
      "added_at": "2025-02-07T08:35:45.884Z"
    }
  ],
  "FARM": [
    {
      "author": "Benzinga Insights",
      "content": "",
      "created_at": "2025-02-06T21:41:18Z",
      "headline": "Farmer Bros: Q2 Earnings Insights",
      "id": 43546460,
      "images": [
        {
          "size": "large",
          "url": "https://cdn.benzinga.com/files/imagecache/2048x1536xUP/images/story/2023/analyst_ratings_image_0.jpeg"
        },
        {
          "size": "small",
          "url": "https://cdn.benzinga.com/files/imagecache/1024x768xUP/images/story/2023/analyst_ratings_image_0.jpeg"
        },
        {
          "size": "thumb",
          "url": "https://cdn.benzinga.com/files/imagecache/250x187xUP/images/story/2023/analyst_ratings_image_0.jpeg"
        }
      ],
      "source": "benzinga",
      "summary": " ",
      "symbols": [
        "FARM"
      ],
      "updated_at": "2025-02-06T21:41:18Z",
      "url": "https://www.benzinga.com/insights/earnings/25/02/43546460/farmer-bros-q2-earnings-insights",
      "added_at": "2025-02-07T09:26:12.680Z"
    },
    {
      "author": "Benzinga Newsdesk",
      "content": "",
      "created_at": "2025-02-06T21:25:31Z",
      "headline": "Farmer Bros Q2 EPS $0.01 Beats $(0.06) Estimate, Sales $90.02M Miss $91.16M Estimate",
      "id": 43545589,
      "images": [],
      "source": "benzinga",
      "summary": "",
      "symbols": [
        "FARM"
      ],
      "updated_at": "2025-02-06T21:25:31Z",
      "url": "https://www.benzinga.com/news/earnings/25/02/43545589/farmer-bros-q2-eps-0-01-beats-0-06-estimate-sales-90-02m-miss-91-16m-estimate",
      "added_at": "2025-02-07T09:26:12.681Z"
    }
  ],
  "PGY": [
    {
      "author": "Benzinga Newsdesk",
      "content": "",
      "created_at": "2025-02-07T11:30:05Z",
      "headline": "Citigroup Upgrades Pagaya Techs to Buy, Raises Price Target to $14.5",
      "id": 43555944,
      "images": [],
      "source": "benzinga",
      "summary": "",
      "symbols": [
        "PGY"
      ],
      "updated_at": "2025-02-07T11:30:06Z",
      "url": "https://www.benzinga.com/news/25/02/43555944/citigroup-upgrades-pagaya-techs-to-buy-raises-price-target-to-14-5",
      "added_at": "2025-02-07T11:33:35.045Z"
    }
  ],
  "ITRM": [
    {
      "author": "Benzinga Newsdesk",
      "content": "",
      "created_at": "2025-02-07T12:02:51Z",
      "headline": "Iterum Therapeutics Expects Its Available Cash To Be Sufficient To Fund Its Operations Into H2 Of 2025",
      "id": 43556552,
      "images": [],
      "source": "benzinga",
      "summary": "",
      "symbols": [
        "ITRM"
      ],
      "updated_at": "2025-02-07T12:02:52Z",
      "url": "https://www.benzinga.com/news/25/02/43556552/iterum-therapeutics-expects-its-available-cash-to-be-sufficient-to-fund-its-operations-into-h2-of-20",
      "added_at": "2025-02-07T12:20:03.339Z"
    },
    {
      "author": "Benzinga Newsdesk",
      "content": "",
      "created_at": "2025-02-07T12:00:49Z",
      "headline": "Iterum Therapeutics Q4 2024 Adj EPS $(0.12) Beats $(0.21) Estimate",
      "id": 43556513,
      "images": [],
      "source": "benzinga",
      "summary": "",
      "symbols": [
        "ITRM"
      ],
      "updated_at": "2025-02-07T12:00:50Z",
      "url": "https://www.benzinga.com/news/earnings/25/02/43556513/iterum-therapeutics-q4-2024-adj-eps-0-12-beats-0-21-estimate",
      "added_at": "2025-02-07T12:20:03.339Z"
    }
  ],
  "RANI": [
    {
      "author": "Benzinga Newsdesk",
      "content": "",
      "created_at": "2025-02-07T12:30:50Z",
      "headline": "HC Wainwright & Co. Reiterates Buy on Rani Therapeutics Hldgs, Maintains $9 Price Target",
      "id": 43557453,
      "images": [],
      "source": "benzinga",
      "summary": "",
      "symbols": [
        "RANI"
      ],
      "updated_at": "2025-02-07T12:30:51Z",
      "url": "https://www.benzinga.com/news/25/02/43557453/hc-wainwright-co-reiterates-buy-on-rani-therapeutics-hldgs-maintains-9-price-target",
      "added_at": "2025-02-07T12:33:36.287Z"
    }
  ],
  "CDT": [
    {
      "author": "Benzinga Newsdesk",
      "content": "",
      "created_at": "2025-02-07T13:03:09Z",
      "headline": "Conduit Pharmaceuticals Transitions To Phase II In Sarborg Collaboration For AI-Driven Drug Development; Phase II To Focus On Personalized Software Dashboards To Enhance Efficiency And Decision-Making",
      "id": 43558146,
      "images": [],
      "source": "benzinga",
      "summary": "",
      "symbols": [
        "CDT"
      ],
      "updated_at": "2025-02-07T13:03:10Z",
      "url": "https://www.benzinga.com/news/25/02/43558146/conduit-pharmaceuticals-transitions-to-phase-ii-in-sarborg-collaboration-for-ai-driven-drug-developm",
      "added_at": "2025-02-07T13:03:36.756Z"
    }
  ],
  "MDAI": [
    {
      "author": "Benzinga Newsdesk",
      "content": "",
      "created_at": "2025-02-07T13:24:41Z",
      "headline": "Spectral AI Announces Completion Of Its Data Analytics For Its U.S. Burn Study",
      "id": 43558829,
      "images": [],
      "source": "benzinga",
      "summary": "",
      "symbols": [
        "MDAI"
      ],
      "updated_at": "2025-02-07T13:24:42Z",
      "url": "https://www.benzinga.com/general/biotech/25/02/43558829/spectral-ai-announces-completion-of-its-data-analytics-for-its-u-s-burn-study",
      "added_at": "2025-02-07T13:28:36.941Z"
    }
  ],
  "REBN": [
    {
      "author": "Benzinga Newsdesk",
      "content": "",
      "created_at": "2025-02-07T13:33:21Z",
      "headline": "Reborn Coffee Enters Securities Purchase Agreement And Common Stock Purchase Agreement For Up to $60M In Financing Commitments With Arena Investors, LP And Arena Business Solutions Global SPC II, Ltd.",
      "id": 43559031,
      "images": [],
      "source": "benzinga",
      "summary": "",
      "symbols": [
        "REBN"
      ],
      "updated_at": "2025-02-07T13:33:22Z",
      "url": "https://www.benzinga.com/news/25/02/43559031/reborn-coffee-enters-securities-purchase-agreement-and-common-stock-purchase-agreement-for-up-to-60m",
      "added_at": "2025-02-07T13:33:36.917Z"
    }
  ],
  "CYTH": [
    {
      "author": "Benzinga Newsdesk",
      "content": "",
      "created_at": "2025-02-07T13:09:55Z",
      "headline": "Cyclo Therapeutics Presents Preliminary Data From Phase 3 TransportNPC Study Of Trappsol With 6 Of 7 Patients Showing Stabilization Or Improvement In Clinical Global Impression Over 48 Weeks; Topline 48-Week Interim Data Expected in H1 2025",
      "id": 43558384,
      "images": [],
      "source": "benzinga",
      "summary": "",
      "symbols": [
        "CYTH"
      ],
      "updated_at": "2025-02-07T13:09:56Z",
      "url": "https://www.benzinga.com/general/biotech/25/02/43558384/cyclo-therapeutics-presents-preliminary-data-from-phase-3-transportnpc-study-of-trappsol-with-6-o",
      "added_at": "2025-02-07T13:46:46.477Z"
    }
  ],
  "SWI": [
    {
      "author": "Benzinga Newsdesk",
      "content": "",
      "created_at": "2025-02-07T13:43:52Z",
      "headline": "SolarWinds To Be Acquired By Turn/River Capital; Shareholders To Receive $18.50/Share With Total Enterprise Value Of $4.4B",
      "id": 43559354,
      "images": [],
      "source": "benzinga",
      "summary": "",
      "symbols": [
        "SWI"
      ],
      "updated_at": "2025-02-07T13:43:53Z",
      "url": "https://www.benzinga.com/m-a/25/02/43559354/solarwinds-to-be-acquired-by-turnriver-capital-shareholders-to-receive-18-50share-with-total-enterpr",
      "added_at": "2025-02-07T13:58:06.080Z"
    },
    {
      "author": "Shivani Kumaresan",
      "content": "",
      "created_at": "2025-02-07T15:18:29Z",
      "headline": "Software Company SolarWinds Agrees To Go Private In $4.4B Deal; Stock Skyrockets",
      "id": 43563232,
      "images": [
        {
          "size": "large",
          "url": "https://cdn.benzinga.com/files/imagecache/2048x1536xUP/images/story/2025/02/07/Businessmen-Making-Handshake-With-Partne.jpeg"
        },
        {
          "size": "small",
          "url": "https://cdn.benzinga.com/files/imagecache/1024x768xUP/images/story/2025/02/07/Businessmen-Making-Handshake-With-Partne.jpeg"
        },
        {
          "size": "thumb",
          "url": "https://cdn.benzinga.com/files/imagecache/250x187xUP/images/story/2025/02/07/Businessmen-Making-Handshake-With-Partne.jpeg"
        }
      ],
      "source": "benzinga",
      "summary": "SolarWinds is set to be acquired by Turn/River Capital for $4.4 billion. Shareholders will get $18.50 per share.",
      "symbols": [
        "SWI"
      ],
      "updated_at": "2025-02-07T15:18:29Z",
      "url": "https://www.benzinga.com/25/02/43563232/software-company-solarwinds-to-go-private-in-44b-deal-stocks-skyrocket",
      "added_at": "2025-02-07T15:18:34.836Z"
    }
  ],
  "TNXP": [
    {
      "author": "Benzinga Newsdesk",
      "content": "",
      "created_at": "2025-02-07T13:33:40Z",
      "headline": "Tonix Pharmaceuticals Reports FY24 Preliminary Financials: $98.8M In Cash And Cash Equivalents As Of December 31, 2024, Revenue Hits ~$10.1M Vs $7.8M YoY",
      "id": 43559033,
      "images": [],
      "source": "benzinga",
      "summary": "",
      "symbols": [
        "TNXP"
      ],
      "updated_at": "2025-02-07T13:33:40Z",
      "url": "https://www.benzinga.com/news/earnings/25/02/43559033/tonix-pharmaceuticals-reports-fy24-preliminary-financials-98-8m-in-cash-and-cash-equivalents-as-of-",
      "added_at": "2025-02-07T14:00:18.356Z"
    }
  ],
  "ULCC": [
    {
      "author": "Benzinga Insights",
      "content": "",
      "created_at": "2025-02-07T13:20:06Z",
      "headline": "Frontier Group Holdings Earnings Review: Q4 Summary",
      "id": 43558691,
      "images": [
        {
          "size": "large",
          "url": "https://cdn.benzinga.com/files/imagecache/2048x1536xUP/images/story/2023/analyst_ratings_image_4.png"
        },
        {
          "size": "small",
          "url": "https://cdn.benzinga.com/files/imagecache/1024x768xUP/images/story/2023/analyst_ratings_image_4.png"
        },
        {
          "size": "thumb",
          "url": "https://cdn.benzinga.com/files/imagecache/250x187xUP/images/story/2023/analyst_ratings_image_4.png"
        }
      ],
      "source": "benzinga",
      "summary": " ",
      "symbols": [
        "ULCC"
      ],
      "updated_at": "2025-02-07T13:20:07Z",
      "url": "https://www.benzinga.com/insights/earnings/25/02/43558691/frontier-group-holdings-earnings-review-q4-summary",
      "added_at": "2025-02-07T14:29:44.945Z"
    },
    {
      "author": "Benzinga Newsdesk",
      "content": "",
      "created_at": "2025-02-07T13:04:25Z",
      "headline": "Frontier Group Holdings Q4 2024 Adj. EPS $0.23 Beats $0.12 Estimate, Sales $1.002B Beat $984.071M Estimate",
      "id": 43558190,
      "images": [],
      "source": "benzinga",
      "summary": "",
      "symbols": [
        "ULCC"
      ],
      "updated_at": "2025-02-07T13:04:25Z",
      "url": "https://www.benzinga.com/news/earnings/25/02/43558190/frontier-group-holdings-q4-2024-adj-eps-0-23-beats-0-12-estimate-sales-1-002b-beat-984-071m-estimat",
      "added_at": "2025-02-07T14:29:44.945Z"
    }
  ],
  "CLSK": [
    {
      "author": "Benzinga Newsdesk",
      "content": "",
      "created_at": "2025-02-07T13:11:12Z",
      "headline": "HC Wainwright & Co. Reiterates Buy on Cleanspark, Maintains $27 Price Target",
      "id": 43558533,
      "images": [],
      "source": "benzinga",
      "summary": "",
      "symbols": [
        "CLSK"
      ],
      "updated_at": "2025-02-07T13:11:13Z",
      "url": "https://www.benzinga.com/news/25/02/43558533/hc-wainwright-co-reiterates-buy-on-cleanspark-maintains-27-price-target",
      "added_at": "2025-02-07T14:32:56.596Z"
    },
    {
      "author": "Benzinga Newsdesk",
      "content": "",
      "created_at": "2025-02-06T21:18:28Z",
      "headline": "Cleanspark Q1 2025 GAAP EPS $0.85 Beats $0.09 Estimate, Sales $162.300M Beat $150.874M Estimate",
      "id": 43545239,
      "images": [],
      "source": "benzinga",
      "summary": "",
      "symbols": [
        "CLSK"
      ],
      "updated_at": "2025-02-06T21:18:29Z",
      "url": "https://www.benzinga.com/news/earnings/25/02/43545239/cleanspark-q1-2025-gaap-eps-0-85-beats-0-09-estimate-sales-162-300m-beat-150-874m-estimate",
      "added_at": "2025-02-07T14:32:56.596Z"
    }
  ],
  "CRNC": [
    {
      "author": "Benzinga Insights",
      "content": "",
      "created_at": "2025-02-07T12:00:37Z",
      "headline": "4 Analysts Assess Cerence: What You Need To Know",
      "id": 43556500,
      "images": [
        {
          "size": "large",
          "url": "https://cdn.benzinga.com/files/imagecache/2048x1536xUP/images/story/2023/analyst_ratings_image_0.jpeg"
        },
        {
          "size": "small",
          "url": "https://cdn.benzinga.com/files/imagecache/1024x768xUP/images/story/2023/analyst_ratings_image_0.jpeg"
        },
        {
          "size": "thumb",
          "url": "https://cdn.benzinga.com/files/imagecache/250x187xUP/images/story/2023/analyst_ratings_image_0.jpeg"
        }
      ],
      "source": "benzinga",
      "summary": " ",
      "symbols": [
        "CRNC"
      ],
      "updated_at": "2025-02-07T12:00:38Z",
      "url": "https://www.benzinga.com/insights/analyst-ratings/25/02/43556500/4-analysts-assess-cerence-what-you-need-to-know",
      "added_at": "2025-02-07T14:33:58.672Z"
    },
    {
      "author": "Benzinga Newsdesk",
      "content": "",
      "created_at": "2025-02-07T11:36:11Z",
      "headline": "Needham Reiterates Buy on Cerence, Maintains $16 Price Target",
      "id": 43555994,
      "images": [],
      "source": "benzinga",
      "summary": "",
      "symbols": [
        "CRNC"
      ],
      "updated_at": "2025-02-07T11:36:12Z",
      "url": "https://www.benzinga.com/news/25/02/43555994/needham-reiterates-buy-on-cerence-maintains-16-price-target",
      "added_at": "2025-02-07T14:33:58.672Z"
    },
    {
      "author": "Benzinga Insights",
      "content": "",
      "created_at": "2025-02-06T21:42:14Z",
      "headline": "Earnings Summary: Cerence Q1",
      "id": 43546520,
      "images": [
        {
          "size": "large",
          "url": "https://cdn.benzinga.com/files/imagecache/2048x1536xUP/images/story/2023/analyst_ratings_image_2.jpeg"
        },
        {
          "size": "small",
          "url": "https://cdn.benzinga.com/files/imagecache/1024x768xUP/images/story/2023/analyst_ratings_image_2.jpeg"
        },
        {
          "size": "thumb",
          "url": "https://cdn.benzinga.com/files/imagecache/250x187xUP/images/story/2023/analyst_ratings_image_2.jpeg"
        }
      ],
      "source": "benzinga",
      "summary": " ",
      "symbols": [
        "CRNC"
      ],
      "updated_at": "2025-02-06T21:42:15Z",
      "url": "https://www.benzinga.com/insights/earnings/25/02/43546520/earnings-summary-cerence-q1",
      "added_at": "2025-02-07T14:33:58.672Z"
    },
    {
      "author": "Benzinga Newsdesk",
      "content": "",
      "created_at": "2025-02-06T21:23:28Z",
      "headline": "Cerence Expects Q2 Revenue Of $74M - $77M, Est $61.184M; FY25 Guidance Remains Unchanged",
      "id": 43545519,
      "images": [],
      "source": "benzinga",
      "summary": "",
      "symbols": [
        "CRNC"
      ],
      "updated_at": "2025-02-06T21:23:29Z",
      "url": "https://www.benzinga.com/news/25/02/43545519/cerence-expects-q2-revenue-of-74m-77m-est-61-184m-fy25-guidance-remains-unchanged",
      "added_at": "2025-02-07T14:33:58.672Z"
    },
    {
      "author": "Benzinga Newsdesk",
      "content": "",
      "created_at": "2025-02-06T21:08:04Z",
      "headline": "Cerence Q1 2025 Adj EPS $(0.03) Beats $(0.26) Estimate, Sales $50.90M Beat $50.84M Estimate",
      "id": 43544877,
      "images": [],
      "source": "benzinga",
      "summary": "",
      "symbols": [
        "CRNC"
      ],
      "updated_at": "2025-02-06T21:08:05Z",
      "url": "https://www.benzinga.com/news/earnings/25/02/43544877/cerence-q1-2025-adj-eps-0-03-beats-0-26-estimate-sales-50-90m-beat-50-84m-estimate",
      "added_at": "2025-02-07T14:33:58.672Z"
    }
  ],
  "VSAT": [
    {
      "author": "Benzinga Newsdesk",
      "content": "",
      "created_at": "2025-02-06T21:36:11Z",
      "headline": "Viasat Sees FY25 Communication Services Revenue Unchanged, Sees FY25 Capital Expenditures Around $1.1B, FY25 DAT Revenue Growth in Mid-Teens",
      "id": 43546163,
      "images": [],
      "source": "benzinga",
      "summary": "",
      "symbols": [
        "VSAT"
      ],
      "updated_at": "2025-02-06T21:36:12Z",
      "url": "https://www.benzinga.com/news/25/02/43546163/viasat-sees-fy25-communication-services-revenue-unchanged-sees-fy25-capital-expenditures-around-1-1b",
      "added_at": "2025-02-07T14:45:10.703Z"
    },
    {
      "author": "Benzinga Newsdesk",
      "content": "",
      "created_at": "2025-02-06T21:34:32Z",
      "headline": "Viasat Q3 2025 Adj. EPS $0.11 Beats $(0.58) Estimate, Sales $1.124B Beat $1.122B Estimate",
      "id": 43546046,
      "images": [],
      "source": "benzinga",
      "summary": "",
      "symbols": [
        "VSAT"
      ],
      "updated_at": "2025-02-06T21:34:33Z",
      "url": "https://www.benzinga.com/news/earnings/25/02/43546046/viasat-q3-2025-adj-eps-0-11-beats-0-58-estimate-sales-1-124b-beat-1-122b-estimate",
      "added_at": "2025-02-07T14:45:10.703Z"
    }
  ],
  "IREN": [
    {
      "author": "Benzinga Insights",
      "content": "",
      "created_at": "2025-02-07T14:45:29Z",
      "headline": "Looking At IREN's Recent Unusual Options Activity",
      "id": 43561509,
      "images": [
        {
          "size": "large",
          "url": "https://cdn.benzinga.com/files/imagecache/2048x1536xUP/images/story/2023/movers_image_5.jpeg"
        },
        {
          "size": "small",
          "url": "https://cdn.benzinga.com/files/imagecache/1024x768xUP/images/story/2023/movers_image_5.jpeg"
        },
        {
          "size": "thumb",
          "url": "https://cdn.benzinga.com/files/imagecache/250x187xUP/images/story/2023/movers_image_5.jpeg"
        }
      ],
      "source": "benzinga",
      "summary": " ",
      "symbols": [
        "IREN"
      ],
      "updated_at": "2025-02-07T14:45:30Z",
      "url": "https://www.benzinga.com/insights/options/25/02/43561509/looking-at-irens-recent-unusual-options-activity",
      "added_at": "2025-02-07T14:48:33.424Z"
    }
  ],
  "SERV": [
    {
      "author": "Benzinga Newsdesk",
      "content": "",
      "created_at": "2025-02-07T14:58:23Z",
      "headline": "Watching Serve Robotics; Hearing Zacks Newsletter Picks Stock",
      "id": 43562012,
      "images": [],
      "source": "benzinga",
      "summary": "",
      "symbols": [
        "SERV"
      ],
      "updated_at": "2025-02-07T14:58:24Z",
      "url": "https://www.benzinga.com/news/25/02/43562012/watching-serve-robotics-hearing-zacks-newsletter-picks-stock",
      "added_at": "2025-02-07T14:58:39.673Z"
    }
  ],
  "SLRN": [],
  "QSI": [
    {
      "author": "Benzinga Newsdesk",
      "content": "",
      "created_at": "2025-02-07T15:20:56Z",
      "headline": "Alliance Global Partners Initiates Coverage On Quantum-Si with Buy Rating, Announces Price Target of $3.75",
      "id": 43563365,
      "images": [],
      "source": "benzinga",
      "summary": "",
      "symbols": [
        "QSI"
      ],
      "updated_at": "2025-02-07T15:20:56Z",
      "url": "https://www.benzinga.com/news/25/02/43563365/alliance-global-partners-initiates-coverage-on-quantum-si-with-buy-rating-announces-price-target-of",
      "added_at": "2025-02-07T15:23:39.431Z"
    }
  ],
  "APPS": [],
  "BBAI": [
    {
      "author": "Benzinga Insights",
      "content": "",
      "created_at": "2025-02-07T15:45:32Z",
      "headline": "What the Options Market Tells Us About BigBear.ai Hldgs",
      "id": 43564299,
      "images": [
        {
          "size": "large",
          "url": "https://cdn.benzinga.com/files/imagecache/2048x1536xUP/images/story/2023/movers_image_5.jpeg"
        },
        {
          "size": "small",
          "url": "https://cdn.benzinga.com/files/imagecache/1024x768xUP/images/story/2023/movers_image_5.jpeg"
        },
        {
          "size": "thumb",
          "url": "https://cdn.benzinga.com/files/imagecache/250x187xUP/images/story/2023/movers_image_5.jpeg"
        }
      ],
      "source": "benzinga",
      "summary": " ",
      "symbols": [
        "BBAI"
      ],
      "updated_at": "2025-02-07T15:45:32Z",
      "url": "https://www.benzinga.com/insights/options/25/02/43564299/what-the-options-market-tells-us-about-bigbear-ai-hldgs",
      "added_at": "2025-02-07T15:48:36.572Z"
    }
  ]
}